Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes

Bah, Aïcha; Cardoso, Marcia; Seghatchian, Jerard; Goodrich, Raymond P.

doi:10.1016/j.transci.2018.09.004

Cited by 8 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…137 Knowledge about what levels of inactivation are necessary to prevent disease transmission are not clear or uniform for all agents. 138,139 Examples are now available from completed and ongoing routine use studies that suggest that while disease transmission may be significantly curtailed, some breakthrough events may still be anticipated including cases where pathogen loads in donated products may exceed inactivation potential 123 or where the PRT method may prove ineffective against specific types of resistant agents such as nonenveloped viruses. 140 Not all methods will deliver the same outcomes in pathogen load reduction capabilities; hence continued field evaluation of what is needed to significantly reduce the probability of disease transmission in areas where such diseases are endemic will be necessary to fully determine the extent of effectiveness.…”

Section: Session 3 Pathogen Reduction Technologies For Whole Blood An...mentioning

confidence: 99%

High-Power Laser-Plasma Interaction

Liu

Tripathi

Eliasson

2019

View full text Add to dashboard Cite

experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, and industry gathered at the Food and Drug Administration (FDA) White Oak Campus in Silver Spring, Maryland, for a 2-day public workshop entitled "Pathogen Reduction Technologies for Blood Safety." The workshop opened with welcome remarks from Dr. Nicole Verdun, Director, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA, followed by introductory remarks from Dr. Peter Marks, Director, CBER, FDA. The first day of the workshop focused on blood-borne infectious agents and their impact on blood safety, experiences of the American Red Cross, and other blood establishments in implementing FDA-approved pathogen inactivation (PI) technology for plasma and platelets (PLTs) in the United States and novel PRTs under consideration for whole blood (WB) and red blood cells (RBCs).The second day opened with welcome remarks from Dr. Chintamani Atreya, Associate Director for Research, OBRR, CBER, FDA. The focus was on emerging innovations relevant to PRTs and potential alternatives to PRTs. The workshop concluded with remarks on insights for future research and development in this area for blood and blood product safety from infectious agents.A brief introduction of each session by the session moderator followed by a summary of the speaker presentation as submitted by the moderator and speaker are reported here.

show abstract

Section: Session 3 Pathogen Reduction Technologies For Whole Blood An...mentioning

confidence: 99%

High-Power Laser-Plasma Interaction

Liu

Tripathi

Eliasson

2019

View full text Add to dashboard Cite

show abstract

“…Such as enhancing the research and development of recombinant albumin, improving the utilization of ovalbumin and so on ( Rogers et al, 2015 ). In these alternative solutions, recombinant albumin not only has the advantage of being able to be mass-produced at a lower cost, but also avoids the risk of transmission of blood diseases ( Bah et al, 2018 ; Heroes et al, 2020 ). A research team from Wuhan University in China successfully used rice to obtain recombinant human serum albumin, and 1 kg rice yields about 10 g HSA, this trial significantly reduced the cost of HSA ( He et al, 2011 ).…”

Section: Potential Directions For Future Researchmentioning

confidence: 99%

Research progress on albumin-based hydrogels: Properties, preparation methods, types and its application for antitumor-drug delivery and tissue engineering

Meng

Zhu

Deng

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Albumin is derived from blood plasma and is the most abundant protein in blood plasma, which has good mechanical properties, biocompatibility and degradability, so albumin is an ideal biomaterial for biomedical applications, and drug-carriers based on albumin can better reduce the cytotoxicity of drug. Currently, there are numerous reviews summarizing the research progress on drug-loaded albumin molecules or nanoparticles. In comparison, the study of albumin-based hydrogels is a relatively small area of research, and few articles have systematically summarized the research progress of albumin-based hydrogels, especially for drug delivery and tissue engineering. Thus, this review summarizes the functional features and preparation methods of albumin-based hydrogels, different types of albumin-based hydrogels and their applications in antitumor drugs, tissue regeneration engineering, etc. Also, potential directions for future research on albumin-based hydrogels are discussed.

show abstract

“…Some considerations should be made: i) the estimate of "log titer reduction" is commonly used to determine effectiveness of a method and to compare different technology. However, to obtain high rates of agent titer reduction could often be unnecessary and in some cases "log reduction" may not be a good parameter to estimate the blood safety (107). In fact, it is important to consider that bacterial concentration is not very high shortly after collection and production (generally < 100 CFU/product), so a high log reduction capacity is not necessary (108,79).…”

Section: Efficacymentioning

confidence: 99%

New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

Galli

Bruschi

2020

The EuroBiotech Journal

View full text Add to dashboard Cite

Around 70 infectious agents are possible threats for blood safety.The risk for blood recipients is increasing because of new emergent agents like West Nile, Zika and Chikungunya viruses, or parasites such as Plasmodium and Trypanosoma cruzi in non-endemic regions, for instance.Screening programmes of the donors are more and more implemented in several Countries, but these cannot prevent completely infections, especially when they are caused by new agents.Pathogen inactivation (PI) methods might overcome the limits of the screening and different technologies have been set up in the last years.This review aims to describe the most widely used methods focusing on their efficacy as well as on the preservation integrity of blood components.

show abstract

Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes

Cited by 8 publications

References 34 publications

High-Power Laser-Plasma Interaction

High-Power Laser-Plasma Interaction

Research progress on albumin-based hydrogels: Properties, preparation methods, types and its application for antitumor-drug delivery and tissue engineering

New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

Contact Info

Product

Resources

About